Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 10/19 cls
Biogen Idec (BIIB) Baird Christopher Raymond Other Neutral 16% $80.22
Jefferies Adam Walsh Price target Hold
Raymond raised his 3Q07 Tysabri sales estimate to $98M from $91M after BIIB said about 17,000 patients worldwide were receiving the multiple sclerosis (MS) drug as of the end of September (see BioCentury, Oct. 15). However, he lowered his 3Q07 and FY07 EPS estimates to $0.68 from $0.72 and to $2.67 from $2.71 to reflect his increased 3Q07 R&D estimate. Tysabri is partnered with Elan (ELN).
Walsh raised his target to $73 from $52 based on a take-out range of $70-$80 after BIIB said its board of directors authorized management to evaluate the possible sale of the company (see "Change of Control Calculus," A19).
Celera (CRA) JMP Securities Charles Duncan Price target Underperform -2% $15.30
Duncan raised his target to $13 from $11 after CRA completed its acquisition of Berkeley HeartLab for $195M in cash and said it had identified a Genetic Risk Score (GRS) that could be used to predict an increase in risk of coronary heart disease (CHD) (see B4). The company hopes to launch the test in 1Q08.
Cubist (CBST) Cowen Rachel McMinn Other Neutral -1% $22.54
Jefferies Eun Yang Other Buy
McMinn raised her FY07 and FY08 revenue estimates

Read the full 2269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers